Coherus Oncology
CHRS
115 hedge funds and large institutions have $867M invested in Coherus Oncology in 2018 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 48 increasing their positions, 25 reducing their positions, and 15 closing their positions.
92% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 25
80% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 15
58% more call options, than puts
Call options by funds: $14.6M | Put options by funds: $9.23M
42% more capital invested
Capital invested by funds: $611M → $867M (+$256M)
12% more funds holding
Funds holding: 103 → 115 (+12)
2.9% more ownership
Funds ownership: 91.94% → 94.83% (+2.9%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$12.1M |
| 2 |
BlackRock
New York
|
+$11.6M |
| 3 |
HP
Hound Partners
New York
|
+$11.1M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$9.04M |
| 5 |
MWNA
Marshall Wace North America
New York
|
+$8.95M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$8.47M |
| 2 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
-$4.15M |
| 3 |
HCM
Highbridge Capital Management
New York
|
-$4.14M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$2.98M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$2.74M |
CHRS Hedge Fund Activity: Q2 2018 in Review
115 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Coherus Oncology (CHRS) for Q2 2018, worth a combined $867M — up 42% from $611M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new CHRS positions and 15 closed out — a net gain of 12 holders — while 48 added to existing stakes and 25 trimmed.
The largest buyer was Farallon Capital Management, opening a new position worth an estimated $12.1M. The largest seller was Fidelity Investments, cutting an estimated $8.47M.
- 115 institutional investors held Coherus Oncology (CHRS) as of Q2 2018, up from 103 in Q1 2018.
- Funds reported $867M of Coherus Oncology stock for Q2 2018, up 42% quarter-over-quarter.
- 27 funds opened new Coherus Oncology positions in Q2 2018 and 15 closed out, a net change of +12 holders.
- The largest Coherus Oncology buyer in Q2 2018 was Farallon Capital Management, an estimated $12.1M added.
- The largest Coherus Oncology seller in Q2 2018 was Fidelity Investments, an estimated $8.47M sold.
Based on aggregated 13F filings for Q2 2018.